Rhabdomyosarcoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Rhabdomyosarcoma – Pipeline Review, H2 2016’, provides an overview of the Rhabdomyosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma

The report reviews pipeline therapeutics for Rhabdomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rhabdomyosarcoma therapeutics and enlists all their major and minor projects

The report assesses Rhabdomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bellicum Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Celgene Corporation

EpiZyme, Inc.

Exelixis, Inc.

Immunomedics, Inc.

Iproteos S.L.

Merrimack Pharmaceuticals, Inc.

Morphotek, Inc.

Novartis AG

Noxxon Pharma AG

Pfizer Inc.

Shionogi & Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Rhabdomyosarcoma Overview 8

Therapeutics Development 9

Pipeline Products for Rhabdomyosarcoma - Overview 9

Pipeline Products for Rhabdomyosarcoma - Comparative Analysis 10

Rhabdomyosarcoma - Therapeutics under Development by Companies 11

Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes 12

Rhabdomyosarcoma - Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Rhabdomyosarcoma - Products under Development by Companies 15

Rhabdomyosarcoma - Products under Investigation by Universities/Institutes 16

Rhabdomyosarcoma - Companies Involved in Therapeutics Development 17

Bellicum Pharmaceuticals, Inc. 17

Boehringer Ingelheim GmbH 18

Celgene Corporation 19

EpiZyme, Inc. 20

Exelixis, Inc. 21

Immunomedics, Inc. 22

Iproteos S.L. 23

Merrimack Pharmaceuticals, Inc. 24

Morphotek, Inc. 25

Novartis AG 26

Noxxon Pharma AG 27

Pfizer Inc. 28

Shionogi & Co., Ltd. 29

Rhabdomyosarcoma - Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Target 31

Assessment by Mechanism of Action 34

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

afatinib dimaleate - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

axitinib - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

cabozantinib s-malate - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Cellular Immunotherapy for Oncology - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

celyvir - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

crizotinib - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

everolimus - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Hex-hR1 - Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

irinotecan hydrochloride - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

MAL-3101 - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

NOXS-93 - Drug Profile 116

Product Description 116

Mechanism Of Action 116

R&D Progress 116

ontuxizumab - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

paclitaxel albumin bound - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

pazopanib hydrochloride - Drug Profile 127

Product Description 127

Mechanism Of Action 127

R&D Progress 127

S-588410 - Drug Profile 134

Product Description 134

Mechanism Of Action 134

R&D Progress 134

Synthetic Peptides for Rhabdomyosarcoma - Drug Profile 136

Product Description 136

Mechanism Of Action 136

R&D Progress 136

tazemetostat - Drug Profile 137

Product Description 137

Mechanism Of Action 137

R&D Progress 137

Rhabdomyosarcoma - Dormant Projects 144

Rhabdomyosarcoma - Discontinued Products 145

Appendix 146

Methodology 146

Coverage 146

Secondary Research 146

Primary Research 146

Expert Panel Validation 146

Contact Us 146

Disclaimer 147

List of Tables

List of Tables

Number of Products under Development for Rhabdomyosarcoma, H2 2016 9

Number of Products under Development for Rhabdomyosarcoma – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Rhabdomyosarcoma – Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 17

Rhabdomyosarcoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 18

Rhabdomyosarcoma – Pipeline by Celgene Corporation, H2 2016 19

Rhabdomyosarcoma – Pipeline by EpiZyme, Inc., H2 2016 20

Rhabdomyosarcoma – Pipeline by Exelixis, Inc., H2 2016 21

Rhabdomyosarcoma – Pipeline by Immunomedics, Inc., H2 2016 22

Rhabdomyosarcoma – Pipeline by Iproteos S.L., H2 2016 23

Rhabdomyosarcoma – Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 24

Rhabdomyosarcoma – Pipeline by Morphotek, Inc., H2 2016 25

Rhabdomyosarcoma – Pipeline by Novartis AG, H2 2016 26

Rhabdomyosarcoma – Pipeline by Noxxon Pharma AG, H2 2016 27

Rhabdomyosarcoma – Pipeline by Pfizer Inc., H2 2016 28

Rhabdomyosarcoma – Pipeline by Shionogi & Co., Ltd., H2 2016 29

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Stage and Target, H2 2016 32

Number of Products by Stage and Mechanism of Action, H2 2016 35

Number of Products by Stage and Route of Administration, H2 2016 38

Number of Products by Stage and Molecule Type, H2 2016 40

Rhabdomyosarcoma – Dormant Projects, H2 2016 144

Rhabdomyosarcoma – Discontinued Products, H2 2016 145

List of Figures

List of Figures

Number of Products under Development for Rhabdomyosarcoma, H2 2016 9

Number of Products under Development for Rhabdomyosarcoma – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Top 10 Targets, H2 2016 31

Number of Products by Stage and Top 10 Targets, H2 2016 31

Number of Products by Top 10 Mechanism of Actions, H2 2016 34

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 34

Number of Products by Routes of Administration, H2 2016 37

Number of Products by Stage and Routes of Administration, H2 2016 37

Number of Products by Molecule Types, H2 2016 39

Number of Products by Stage and Molecule Types, H2 2016 39

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports